LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

Strona główna・Stock List・Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc

Closed

SectorHealthcare

628.61 1.61

Buy Sell

Overview

Share price change

24h

Current

Min

618.69

Max

631.75

Key metrics
By Trading Economics
Income	-117M 727M
Sales	-279M 3.6B
P/E Sector Avg	14.661 49.888
EPS	9.47
Dividend yield	0.58
Profit margin	20.17
Employees	15,343
EBITDA	-234M 967M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+34.06% upside

Dividends
By Dow Jones
Dividend yield Sector Avg	0.58% 2.38%
Next Earnings	31 lip 2026

Market Stats
By TradingEconomics
Market Cap	-15B 63B
Previous open	627
Previous close	628.61

News Sentiment

By Acuity

41%

59%

132 / 344 Ranking in Healthcare

Regeneron Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

1 sie 2025, 11:33 UTC

Earnings

Regeneron 2Q Revenue, Adjusted EPS Top Estimates

29 kwi 2026, 12:01 UTC

Earnings

Regeneron Earnings Beat Expectations. Upcoming Cancer Data Matter More for the Stock. -- Barrons.com

23 kwi 2026, 21:48 UTC

Acquisitions, Mergers, Takeovers

Regeneron Shares Up on Trump Drug Pricing Deal -- Barrons.com

11 mar 2026, 11:02 UTC

Market Talk

Sanofi, Regeneron's Eczema Drug Might Face Competition From Pfizer -- Market Talk

14 gru 2025, 08:30 UTC

Acquisitions, Mergers, Takeovers

Kymera Had a Big Week. This Secretive Hedge Fund Bought $172 Million of Its Stock. -- Barrons.com

1 sie 2025, 13:16 UTC

Earnings

Regeneron Stock Is Rising on Earnings. This Sanofi Collaboration Is Helping. -- Barrons.com

1 sie 2025, 12:40 UTC

Earnings

Regeneron Stock Is Rising on Earnings. This Sanofi Collaboration Is Helping. -- Barrons.com

1 sie 2025, 10:41 UTC

Earnings

Regeneron Now Sees 2025 Adjusted R&D $5.1B-$5.2B; Had Seen $5B-$5.2B >REGN

1 sie 2025, 10:41 UTC

Earnings

Regeneron Now Sees 2025 Capital Spending $880M-$950M; Had Seen $850M-$950M >REGN

1 sie 2025, 10:40 UTC

Earnings

Regeneron Now Sees 2025 Adjusted Gross Margin on Net Product Sales About 86%; Had Seen 86%-87% >REGN

1 sie 2025, 10:38 UTC

Earnings

Regeneron: Odronextamab Application Also Impacted by Site Inspection >REGN

1 sie 2025, 10:37 UTC

Earnings

Regeneron Gets FDA Complete Response Letter for Odronextamab in Follicular Lymphoma >REGN

1 sie 2025, 10:35 UTC

Earnings

Regeneron: Anticipate Expeditious Resolution of Filling Issues for Eylea HD >REGN

1 sie 2025, 10:34 UTC

Earnings

Regeneron Cites Observations From FDA General Site Inspection at Filler for Eylea HD >REGN

1 sie 2025, 10:33 UTC

Earnings

Regeneron Sees FDA Approvals Delayed for Eylea HD Indications With August Target Actio Dates >REGN

1 sie 2025, 10:32 UTC

Earnings

Regeneron Pharma: About 45 Product Candidates in Clinical Development >REGN

1 sie 2025, 10:31 UTC

Earnings

Regeneron Pharma 2Q Eylea HD, Eylea U.S. Net Sales Fell 25% to $1.15B >REGN

1 sie 2025, 10:31 UTC

Earnings

Regeneron Pharma: 2Q Dupixent Global Net Sales Recorded by Sanofi Rose 22% to $4.34B >REGN

1 sie 2025, 10:30 UTC

Earnings

Regeneron Pharma 2Q Adj EPS $12.89 >REGN

1 sie 2025, 10:30 UTC

Earnings

Regeneron Pharma 2Q Rev $3.68B >REGN

1 sie 2025, 10:30 UTC

Earnings

Regeneron Pharma 2Q EPS $12.81 >REGN

1 sie 2025, 10:30 UTC

Earnings

Regeneron Pharma 2Q Net $1.39B >REGN

13 cze 2025, 21:42 UTC

Acquisitions, Mergers, Takeovers

Anne Wojcicki Wins Bidding for 23andMe -- 2nd Update

13 cze 2025, 20:45 UTC

Acquisitions, Mergers, Takeovers

23andMe: TTAM Makes Binding Commitments for Additional Consumer Protections and Privacy Safeguards

13 cze 2025, 20:34 UTC

Acquisitions, Mergers, Takeovers

Anne Wojcicki Wins Bidding for 23andMe -- Update

13 cze 2025, 20:14 UTC

Acquisitions, Mergers, Takeovers

Nonprofit Controlled By 23andMe Co-Founder Anne Wojcicki Would Buy the DNA-Testing Company for $305 Million -- WSJ

13 cze 2025, 20:14 UTC

Acquisitions, Mergers, Takeovers

Anne Wojcicki Wins Bidding for 23andMe -- WSJ

13 cze 2025, 20:14 UTC

Acquisitions, Mergers, Takeovers

Regeneron Walks Away From 23andMe Acquisition After Wojcicki's Higher Bid -- WSJ

Peer Comparison

Price change

Regeneron Pharmaceuticals Inc Forecast

Price Target

By TipRanks

34.06% upside

12 Months Forecast

Average 829.77 USD 34.06%

High 995 USD

Low 641 USD

Based on 22 Wall Street analysts offering 12 month price targets forRegeneron Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

22 ratings

Buy

Hold

Sell

Based on 22 analysts giving stock ratings to Regeneron Pharmaceuticals Inc - Dist in the past 3 months.

Sentiment

By Acuity

132 / 344 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.